From PsychonautWiki
Jump to navigation Jump to search

This page has not been approved by the PsychonautWiki administrators.

It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks.

Skull and crossbones darktextred2.png

Serotonin syndrome and/or a prolonged heart QT interval can occur with using SSRIs (such as citalopram, paroxetine, or sertraline) with SNRIs, SRAs (such as MDMA), DXM, serotonergic stimulants (such as cocaine), MAOIs, and RIMAs.

It is strongly discouraged to consume moderate to heavy dosages of these substances together.

Chemical Nomenclature
Common names Zoloft, Lustral
Substitutive name Sertraline
Systematic name (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
Class Membership
Psychoactive class Antidepressant (SSRIs)
Chemical class Tetralin
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Bioavailability 44%
Threshold 0.25 0.25 mg
Light 0.5 - 1 mg
Common 1 - 1.5 mg
Strong 1.5 - 1.5 mg
Heavy 2 mg +
Total 9 - 12 hours
Onset 20 - 40 minutes

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

A tablet of brand-name Zoloft. Dose is 50 miligrams.

Sertraline (also known as Zoloft) is a widely-known SSRI substance and pharmaceutical of the substituted tametraline chemical class that produces anxiolytic and antidepressive effects when administered. Sertraline is primarily prescribed for major depressive disorder in adult outpatients as well as obsessive-compulsive disorder, panic disorder, and social anxiety disorder, in both adults and children.


Sertraline is a substituted tametraline.


Sertraline is a selective reuptake inhibitor of serotonin; this allows sertraline to increase levels of extracellular serotonin, meaning that more serotonin comes into the brain. Sertraline is used for depression because it is hypothesized that people with depression have low serotonin levels.

Sertraline promotes neurogenesis (the growth of neurons). This is a useful property in neurodegenerative diseases, such as Huntington's disease.[1][2][3]

Its metabolite, norsertraline, also inhibits reuptake of serotonin, but more weakly than sertraline. [4][5]

Subjective effects

Physical effects

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

See also

External links


  1. Anacker, C., Zunszain, P. A., Cattaneo, A., Carvalho, L. A., Garabedian, M. J., Thuret, S., ... & Pariante, C. M. (2011). Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Molecular psychiatry, 16(7), 738.
  2. Peng, Q., Masuda, N., Jiang, M., Li, Q., Zhao, M., Ross, C. A., & Duan, W. (2008). The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Experimental neurology, 210(1), 154-163.
  3. Duan, W., Peng, Q., Masuda, N., Ford, E., Tryggestad, E., Ladenheim, B., ... & Ross, C. A. (2008). Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease. Neurobiology of disease, 30(3), 312-322.
  4. Koe, B. K., Weissman, A. L. B. E. R. T., Welch, W. M., & Browne, R. G. (1983). Sertraline, 1S, 4S-N-methyl-4-(3, 4-dichlorophenyl)-1, 2, 3, 4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. Journal of Pharmacology and Experimental Therapeutics, 226(3), 686-700.
  5. Wong, D. T., Bymaster, F. P., & Engleman, E. A. (1995). Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life sciences, 57(5), 411-441.
  6. Didham, R. C., McConnell, D. W., Blair, H. J., & Reith, D. M. (2005). Suicide and self‐harm following prescription of SSRIs and other antidepressants: confounding by indication. British journal of clinical pharmacology, 60(5), 519-525.